HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Appendices Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (21) Citing Articles via Google Scholar Google Scholar Articles by Friedman, D. S. Articles by Hahn, S. R. Search for Related Content PubMed PubMed Citation Articles by Friedman, D. S. Articles by Hahn, S. R.

Using Pharmacy Claims Data to Study Adherence to Glaucoma Medications: Methodology and Findings of the Glaucoma Adherence and Persistency Study (GAPS)

¹From the Wilmer Eye Institute, Baltimore, Maryland; the ²Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; ³HealthCore, Inc., Wilmington, Delaware; ⁴Pfizer Inc., New York, New York; the ⁵Department of Ophthalmology and Visual Sciences, University of Louisville School of Medicine, Louisville, Kentucky; the ⁶Albert Einstein College of Medicine, Bronx, New York; and ⁷Medintel On-Call, Pleasantville, New York.

PURPOSE. To develop methods for investigating adherence to glaucoma medications by using a modified claims data-based measure of adherence, validation by chart review, and patient and physician interviews.

METHODS. Data from administrative claims of 13,956 subjects receiving an initial glaucoma medication, and data from overlapping samples of 300 patients’ charts, 300 interviews of patients, and 103 interviews of physicians were analyzed and compared.

RESULTS. The mean medication possession ratio (MPR) was 0.64 (median 0.57) for the 13,956 subjects. Although 59% potentially had an ocular hypotensive agent at 12 months, only 10% had such medication available continuously. Chart review revealed that 31% of subjects "new to therapy" in claims data had actually been previously treated; and that 90% of the 17% who had medication added to initial monotherapy were misclassified by claims-based algorithms as medication switches or no change. Twenty percent of surveyed patients received samples on a regular basis and had lower MPR than those who did not (P < 0.05).

CONCLUSIONS. Large pharmacy databases offer insight into medication usage but are vulnerable to errors from sampling (since patients who receive samples will be considered to have poor adherence), misidentification of newly treated patients, and misclassification of added versus switched medications. That a large proportion of patients stop and restart medications makes MPR a robust measure of adherence over time that reflects the resumption of medication after a gap in adherence. The data confirm that adherence to treatment with glaucoma medications is poor, similar to adherence in patients with other chronic diseases.

This article has been cited by other articles:

				J. L. Stone, A. L. Robin, G. D. Novack, D. W. Covert, and G. D. Cagle An Objective Evaluation of Eyedrop Instillation in Patients With Glaucoma Arch Ophthalmol, June 1, 2009; 127(6): 732 - 736. [Abstract] [Full Text] [PDF]

				B. W. Lee, P. Sathyan, R. K. John, K. Singh, and A. L. Robin Predictors of and Barriers Associated With Poor Follow-up in Patients With Glaucoma in South India Arch Ophthalmol, October 1, 2008; 126(10): 1448 - 1454. [Abstract] [Full Text] [PDF]